BioSpace News Archive

Tenaya Therapeutics, Inc. announced today that it is scheduled to participate in the Hypertrophic Cardiomyopathy Medical Society’s (HCMS) inaugural 2022 Scientific Sessions taking place September 30, 2022, virtually and in National Harbor, MD.

Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, announced the appointment of Anne Sullivan as Chief Business Officer.

Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces that its lead product, VIVO™ (View Into Ventricular Onset), will be featured in presentations by three physicians working in the field of cardiac electrophysiology at the Sixth Annual Society of Cardiac Robotic Navigation (SCRN) meeting being held September 29-30 in Budapest, Hungary.

EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, today announced that its physicians will deliver nine scientific research presentations and more than 40 instruction courses, skills transfer sessions and symposia at the upcoming American Academy of Ophthalmology (AAO) Meeting September 30 - October 3 in Chicago.

Myonex, a leading global clinical trial supply company, announces the launch of the first and only on-demand local drug sourcing in Europe.

Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle nucleic acid delivery platform, and Centre National de Recherche et de Formation sur le Paludisme, the Burkina Faso site team lead by Dr. Gansane Adama, announced that enrollment is now complete into the single and two-dose cohorts of the Phase 2 clinical trial of Covigenix VAX-001-1b, its COVID-19 DNA vaccine.

Cure Rare Disease, a clinical-stage nonprofit biotechnology company, has acquired its first laboratory space at 4 Research Drive in Woodbridge, Connecticut, where the organization will relocate its headquarters and expand its research and development operations.

SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors.

Ventus Therapeutics, Inc. announced that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.

Societal CDMO, Inc. announced that it has signed multiple CDMO service agreements with both new and existing customers.